Public market insider buying at Valeo Pharma (VPH)

Public market insider buying at Valeo Pharma (C:VPH)

Updated Thursday Jun 23, 2022 02:03 AM EDT
100079 Canada Inc., a 10% Holder, acquired 299,500 Common Shares Class A on a direct ownership basis at prices ranging from $0.580 to $0.619 between June 20th, 2022 and June 21st, 2022. This represents a $181,321 investment into the company's shares and an account share holdings change of 2.6%.

Valeo Pharma is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Valeo Pharma Inc. is a Canada-based specialty pharmaceutical company. The Company acquires or in-licenses brand and hospital specialty products for sale in Canada. The Company is focused on four therapeutic areas, which includes respiratory, oncology, specialty products and neurology. Its respiratory product is Enerzair breezhaler and Atectura breezhaler; its oncology product is Yondelis; its specialty product includes Redesca, Ametop Gel, and M-Eslon and its neurology product is Onstryv. The Company has eight marketed brands and four additional products. Its wholly owned subsidiary is VPI Pharmaceuticals Inc.(VPI). Valeo Pharma Inc. (VPH) has a high amount of executive buying compared to its small-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $181,321.

VPH Insider Holdings Chart

Issuer details as of Jun 23, 2022 2:03 ET

Latest Price
0.66
1 Day Change
0.00%
52 Week High
0.97
52 Week Low
0.49
QMV ($Mils)
53,888,405
Issuer website: https://valeopharma.com/


Top